{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:25:16Z","timestamp":1792671916006,"version":"4.5.0"},"reference-count":85,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Diabetic kidney disease is a frequent microvascular complication of diabetes and is currently the leading cause of chronic kidney disease and end-stage kidney disease worldwide. Although the prevalence of other complications of diabetes is falling, the number of diabetic patients with end-stage kidney disease in need of kidney replacement therapy is rising. In addition, these patients have extremely high cardiovascular risk. It is more than evident that there is a high unmet treatment need in patients with diabetic kidney disease. Finerenone is a novel nonsteroidal mineralocorticoid receptor antagonist used for treating diabetic kidney disease. It has predominant anti-fibrotic and anti-inflammatory effects and exhibits several renal and cardiac protective effects. This review article summarizes the current knowledge and future prospects of finerenone in treating patients with kidney disease.<\/jats:p>","DOI":"10.3390\/ph17040418","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T11:34:58Z","timestamp":1711452898000},"page":"418","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Finerenone: From the Mechanism of Action to Clinical Use in Kidney Disease"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1314-4428","authenticated-orcid":false,"given":"Nejc","family":"Piko","sequence":"first","affiliation":[{"name":"Department of Dialysis, Clinic for Internal Medicine, University Medical Centre Maribor, 2000 Maribor, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastjan","family":"Bevc","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Clinic for Internal Medicine, University Medical Centre Maribor, 2000 Maribor, Slovenia"},{"name":"Medical Faculty, University of Maribor, 2000 Maribor, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radovan","family":"Hojs","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Clinic for Internal Medicine, University Medical Centre Maribor, 2000 Maribor, Slovenia"},{"name":"Medical Faculty, University of Maribor, 2000 Maribor, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7395-752X","authenticated-orcid":false,"given":"Robert","family":"Ekart","sequence":"additional","affiliation":[{"name":"Department of Dialysis, Clinic for Internal Medicine, University Medical Centre Maribor, 2000 Maribor, Slovenia"},{"name":"Medical Faculty, University of Maribor, 2000 Maribor, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.2337\/dc14-1296","article-title":"Diabetic kidney disease: A report from an ADA Consensus Conference","volume":"37","author":"Tuttle","year":"2014","journal-title":"Diabetes Care"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2215\/CJN.02980322","article-title":"Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease","volume":"17","author":"Tuttle","year":"2022","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.xkme.2021.04.018","article-title":"Retinopathy and Risk of Kidney Disease in Persons With Diabetes","volume":"3","author":"Hong","year":"2021","journal-title":"Kidney Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S2213-8587(20)30402-2","article-title":"Trends in the incidence of diagnosed diabetes: A multicountry analysis of aggregate data from 22 million diagnoses in high-income and middle-income settings","volume":"9","author":"Magliano","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e227705","DOI":"10.1001\/jamanetworkopen.2022.7705","article-title":"Potential Gains in Life Expectancy Associated With Achieving Treatment Goals in US Adults With Type 2 Diabetes","volume":"5","author":"Kianmehr","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_7","first-page":"49","article-title":"Diabetic kidney disease: World wide difference of prevalence and risk factors","volume":"5","author":"Gheith","year":"2016","journal-title":"J. Nephropharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1053\/j.ackd.2017.10.011","article-title":"The Global Epidemiology of Diabetes and Kidney Disease","volume":"25","author":"Koye","year":"2018","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_9","first-page":"286","article-title":"Changes in diabetes-related complications in the United States","volume":"371","author":"Gregg","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association","volume":"139","author":"Benjamin","year":"2019","journal-title":"Circulation"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/ndt\/gfac140","article-title":"High unmet treatment needs in patients with chronic kidney disease and type 2 diabetes: Real-world evidence from a US claims database","volume":"38","author":"Fried","year":"2023","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.kint.2022.05.012","article-title":"Molecular mechanisms and therapeutic targets for diabetic kidney disease","volume":"102","author":"Tuttle","year":"2022","journal-title":"Kidney Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1172\/JCI72271","article-title":"Molecular mechanisms of diabetic kidney disease","volume":"124","author":"Reidy","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Sakashita, M., Tanaka, T., and Inagi, R. (2021). Metabolic Changes and Oxidative Stress in Diabetic Kidney Disease. Antioxidants, 10.","DOI":"10.3390\/antiox10071143"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4161\/oxim.3.2.11148","article-title":"Advanced glycation end products, oxidative stress and diabetic nephropathy","volume":"3","author":"Yamagishi","year":"2010","journal-title":"Oxid. Med. Cell Longev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"104175","DOI":"10.1016\/j.lpm.2023.104175","article-title":"Renal hemodynamic changes in patients with type 2 diabetes and their clinical impact","volume":"52","author":"Saulnier","year":"2023","journal-title":"Presse Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1681\/ASN.2016060666","article-title":"Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment","volume":"28","author":"Tonneijck","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Banerjee, D., Winocour, P., Chowdhury, T.A., De, P., Wahba, M., Montero, R., Fogarty, D., Frankel, A.H., Karalliedde, J., and Mark, P.B. (2022). Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021. BMC Nephrol., 23.","DOI":"10.1186\/s12882-021-02587-5"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"F473","DOI":"10.1152\/ajprenal.00503.2013","article-title":"The physical basis of renal fibrosis: Effects of altered hydrodynamic forces on kidney homeostasis","volume":"306","author":"Grabias","year":"2014","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Zhao, L., Zou, Y., and Liu, F. (2020). Transforming Growth Factor-Beta1 in Diabetic Kidney Disease. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.00187"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"F716","DOI":"10.1152\/ajprenal.00314.2016","article-title":"Immunity and inflammation in diabetic kidney disease: Translating mechanisms to biomarkers and treatment targets","volume":"312","author":"Pichler","year":"2017","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/ki.2014.322","article-title":"Revisiting inflammation in diabetic nephropathy: The role of the Nlrp3 inflammasome in glomerular resident cells","volume":"87","author":"Sakai","year":"2015","journal-title":"Kidney Int."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic Kidney Disease: Challenges, Progress, and Possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000528783","article-title":"Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists","volume":"54","author":"Mende","year":"2023","journal-title":"Am. J. Nephrol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"78","DOI":"10.2174\/1574884713666181116100946","article-title":"The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic Nephropathy","volume":"14","author":"Goenka","year":"2019","journal-title":"Curr. Clin. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"754239","DOI":"10.3389\/fphar.2021.754239","article-title":"Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease","volume":"12","author":"Kawanami","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Zhao, H., Yang, C.E., Liu, T., Zhang, M.X., Niu, Y., Wang, M., and Yu, J. (2023). The roles of gut microbiota and its metabolites in diabetic nephropathy. Front. Microbiol., 14.","DOI":"10.3389\/fmicb.2023.1207132"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Jin, H., Kim, Y.A., Lee, Y., Kwon, S.H., Do, A.R., Seo, S., Won, S., and Seo, J.H. (2023). Identification of genetic variants associated with diabetic kidney disease in multiple Korean cohorts via a genome-wide association study mega-analysis. BMC Med., 21.","DOI":"10.1186\/s12916-022-02723-4"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s11892-013-0395-7","article-title":"Temporal profile of diabetic nephropathy pathologic changes","volume":"13","author":"Ponchiardi","year":"2013","journal-title":"Curr. Diab. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/jcp.21856","article-title":"Hyperglycemia and mechanical stress: Targeting the renal podocyte","volume":"221","author":"Lewko","year":"2009","journal-title":"J. Cell Physiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1046\/j.1523-1755.2000.00223.x","article-title":"Evolution of incipient nephropathy in type 2 diabetes mellitus","volume":"58","author":"Lemley","year":"2000","journal-title":"Kidney Int."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"15018","DOI":"10.1038\/nrdp.2015.18","article-title":"Diabetic kidney disease","volume":"1","author":"Thomas","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1053\/j.ackd.2014.03.003","article-title":"Cardiovascular complications of diabetic kidney disease","volume":"21","author":"Patel","year":"2014","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2023.04.052","article-title":"Cardiovascular Outcomes in Patients With Diabetes and Kidney Disease: JACC Review Topic of the Week","volume":"82","author":"Morales","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.2337\/db08-1543","article-title":"The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes","volume":"58","author":"Groop","year":"2009","journal-title":"Diabetes"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e002408","DOI":"10.1136\/bmjdrc-2021-002408","article-title":"Interplay between worsening kidney function and cardiovascular events in patients with type 2 diabetes: An analysis from the ACCORD trial","volume":"9","author":"Ferreira","year":"2021","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1160\/TH13-01-0004","article-title":"Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity","volume":"110","author":"Baber","year":"2013","journal-title":"Thromb. Haemost."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000111829","article-title":"Chronic kidney disease is associated with angiographic coronary artery disease","volume":"28","author":"Chonchol","year":"2008","journal-title":"Am. J. Nephrol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1161\/CIRCULATIONAHA.108.816082","article-title":"Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study","volume":"119","author":"Go","year":"2009","journal-title":"Circulation"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Swamy, S., Noor, S.M., and Mathew, R.O. (2023). Cardiovascular Disease in Diabetes and Chronic Kidney Disease. J. Clin. Med., 12.","DOI":"10.3390\/jcm12226984"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/sj.bjp.0704131","article-title":"Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats","volume":"133","author":"Miric","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1210\/en.2006-0944","article-title":"Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus","volume":"147","author":"Guo","year":"2006","journal-title":"Endocrinology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/sj.ki.5000438","article-title":"Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats","volume":"70","author":"Han","year":"2006","journal-title":"Kidney Int."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ejphar.2008.06.019","article-title":"Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats","volume":"589","author":"Taira","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"101190","DOI":"10.1016\/j.diabet.2020.08.005","article-title":"Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: Data from the MIRAD trial","volume":"47","author":"Johansen","year":"2021","journal-title":"Diabetes Metab."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejim.2013.11.007","article-title":"Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: An emerging paradigm in diabetic nephropathy: A systematic review","volume":"25","author":"Mavrakanas","year":"2014","journal-title":"Eur. J. Intern. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jchf.2022.06.010","article-title":"Steroidal MRA Across the Spectrum of Renal Function: A Pooled Analysis of RCTs","volume":"10","author":"Ferreira","year":"2022","journal-title":"JACC Heart Fail."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/01.RES.67.6.1355","article-title":"Remodeling of the rat right and left ventricles in experimental hypertension","volume":"67","author":"Brilla","year":"1990","journal-title":"Circ. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1440-1681.1987.tb02422.x","article-title":"High affinity aldosterone binding sites (type I receptors) in rat heart","volume":"14","author":"Pearce","year":"1987","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1210\/endo-125-4-2224","article-title":"Vascular type I aldosterone binding sites are physiological mineralocorticoid receptors","volume":"125","author":"Funder","year":"1989","journal-title":"Endocrinology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"T125","DOI":"10.1530\/JOE-16-0600","article-title":"30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development","volume":"234","author":"Kolkhof","year":"2017","journal-title":"J. Endocrinol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/ejhf.888","article-title":"Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease","volume":"19","author":"Bramlage","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Di Lullo, L., Lavalle, C., Scatena, A., Mariani, M.V., Ronco, C., and Bellasi, A. (2023). Finerenone: Questions and Answers-The Four Fundamental Arguments on the New-Born Promising Non-Steroidal Mineralocorticoid Receptor Antagonist. J. Clin. Med., 12.","DOI":"10.3390\/jcm12123992"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s10157-020-01963-z","article-title":"Apararenone in patients with diabetic nephropathy: Results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study","volume":"25","author":"Wada","year":"2021","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/hepr.13695","article-title":"Efficacy and safety of apararenone (MT-3995) in patients with nonalcoholic steatohepatitis: A randomized controlled study","volume":"51","author":"Okanoue","year":"2021","journal-title":"Hepatol. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1093\/ckj\/sfad139","article-title":"Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: A clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA)","volume":"16","author":"Sarafidis","year":"2023","journal-title":"Clin. Kidney J."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"896947","DOI":"10.3389\/fphar.2022.896947","article-title":"Efficacy and Safety of Non-Steroidal Mineralocorticoid Receptor Antagonists in Patients With Chronic Kidney Disease and Type 2 Diabetes: A Systematic Review Incorporating an Indirect Comparisons Meta-Analysis","volume":"13","author":"Jiang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1159\/000506275","article-title":"Finerenone Reduces Intrinsic Arterial Stiffness in Munich Wistar Fr\u00f6mter Rats, a Genetic Model of Chronic Kidney Disease","volume":"51","author":"Schulz","year":"2020","journal-title":"Am. J. Nephrol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3389\/fphar.2018.01131","article-title":"Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress","volume":"9","author":"Somoza","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone\u2019s Antifibrotic Activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: The FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/ckj\/sfac234","article-title":"A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease","volume":"16","author":"Agarwal","year":"2023","journal-title":"Clin. Kidney J."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): A phase 2, randomised, double-blind, placebo-controlled trial","volume":"394","author":"Agarwal","year":"2019","journal-title":"Lancet"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s40262-021-01083-1","article-title":"Finerenone Dose-Exposure-Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria","volume":"61","author":"Goulooze","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"108411","DOI":"10.1016\/j.jdiacomp.2023.108411","article-title":"Design and rationale of FINE-REAL: A prospective study of finerenone in clinical practice","volume":"37","author":"Desai","year":"2023","journal-title":"J. Diabetes Complicat."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"110908","DOI":"10.1016\/j.diabres.2023.110908","article-title":"Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial","volume":"204","author":"Heerspink","year":"2023","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.kisu.2021.11.008","article-title":"Considerations for the future: Current and future treatment paradigms with mineralocorticoid receptor antagonists-unmet needs and underserved patient cohorts","volume":"12","author":"Epstein","year":"2022","journal-title":"Kidney Int. Suppl."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12933-023-01899-0","article-title":"The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction","volume":"22","author":"Kintscher","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s12933-023-02053-6","article-title":"Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands","volume":"22","author":"Quist","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1159\/000513698","article-title":"The 2020 Updated KDOQI Clinical Practice Guidelines for Nutrition in Chronic Kidney Disease","volume":"50","author":"Ikizler","year":"2021","journal-title":"Blood Purif"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Kearney, J., and Gnudi, L. (2023). The Pillars for Renal Disease Treatment in Patients with Type 2 Diabetes. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15051343"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"136","DOI":"10.23876\/j.krcp.22.001","article-title":"GLP-1 receptor agonists in diabetic kidney disease: Current evidence and future directions","volume":"41","author":"Yu","year":"2022","journal-title":"Kidney Res. Clin. Pract."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1681\/ASN.0000000000000186","article-title":"Finerenone Added to RAS\/SGLT2 Blockade for CKD in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3-\/- Mice","volume":"34","author":"Zhu","year":"2023","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1161\/HYPERTENSIONAHA.122.19207","article-title":"Mineralocorticoid Receptor Antagonism by Finerenone Attenuates Established Pulmonary Hypertension in Rats","volume":"79","author":"Tu","year":"2022","journal-title":"Hypertension"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"sfad249","DOI":"10.1093\/ckj\/sfad249","article-title":"Additive effects of dapagliflozin and finerenone on albuminuria in non-diabetic CKD: An open-label randomized clinical trial","volume":"17","author":"Thomsen","year":"2024","journal-title":"Clin. Kidney J."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jacc.2021.04.079","article-title":"Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes","volume":"78","author":"Filippatos","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Shah, M., Awad, A.S., and Abdel-Rahman, E.M. (2023). Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease. J. Clin. Med., 12.","DOI":"10.3390\/jcm12196285"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/4\/418\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:18:34Z","timestamp":1760105914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/4\/418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,26]]},"references-count":85,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["ph17040418"],"URL":"https:\/\/doi.org\/10.3390\/ph17040418","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,26]]}}}